eligibility_summary
Eligible: patients ≤25 with relapsed/refractory ALL planned for licensed CD19 CAR-T therapy (tisagenlecleucel) who provide informed consent. Exclude: those receiving a different CD19 CAR-T on a clinical trial, or anyone the investigator believes cannot adhere to the protocol.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study type: Observational. Participants receive the licensed product tisagenlecleucel (Kymriah). Drug/intervention: Tisagenlecleucel is an autologous, gene‑modified cellular immunotherapy (CD19‑directed CAR T cells) incorporating an anti‑CD19 scFv with 4‑1BB costimulatory and CD3ζ signaling domains. Mechanism of action: CAR engagement of CD19 on B cells triggers T‑cell activation, proliferation, and cytotoxic killing of CD19+ leukemic blasts, the 4‑1BB domain supports expansion and persistence. Targets: CD19 on B cells (B‑ALL), and T‑cell activation/costimulation pathways (CD3ζ/4‑1BB). Aim: Evaluate CAR T persistence over time and factors causing loss of persistence. No experimental drugs added.